Programs
DELIVERING THE FUTURE OF GENE THERAPY
AVB-101
Our lead program, AVB-101, a gene therapy being developed for people living with frontotemporal dementia with a mutation in their GRN gene (FTD-GRN), is in Phase 1/2 clinical trial in UK, Europe, USA and Canada.
AVB-307
An intravitreally-delivered AAV optogenetic therapy for the treatment of retinal dystrophies is current being evaluated clinical trials in retinitis pigmentosa and geographic atrophy.
PRECLINICAL PIPELINE
AviadoBio’s proprietary platforms, including intrathalamic and vMiX™ RNA silencing system, plus expertise in intravitreal, and blood-brain barrier (BBB)-penetrant delivery approaches, enable precise, durable therapeutic expression across complex neural systems such as the brain and retina.
Science and Innovation
Find out what makes AviadoBio’s technology platform stand out from Alex Bloom, Chief Technology Officer.
FRONTOTEMPORAL DEMENTIA
AMYOTROPHIC LATERAL SCLEROSIS
Retinitis Pigmentosa
Alzheimer’s disease and other tauopathies
Alzheimer’s disease and other tauopathies are a group of progressive brain disorders characterized by abnormal changes in tau, a protein that normally supports and stabilizes neurons. In these conditions, tau becomes dysfunctional, clumps together, and disrupts communication between brain cells, ultimately leading to cognitive decline, memory loss, and changes in behavior or movement.